Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
19 06 2023
Historique:
pmc-release: 19 06 2024
medline: 21 6 2023
pubmed: 19 6 2023
entrez: 19 6 2023
Statut: epublish

Résumé

Postoperative pancreatic fistula (POPF) is one of the most frequent and potentially life-threatening complications following pancreatic surgery. Fibrin sealants have been used in some centres to reduce POPF rate. However, the use of fibrin sealant during pancreatic surgery is controversial. This is an update of a Cochrane Review last published in 2020. To evaluate the benefits and harms of fibrin sealant use for the prevention of POPF (grade B or C) in people undergoing pancreatic surgery compared to no fibrin sealant use. We searched CENTRAL, MEDLINE, Embase, two other databases, and five trials registers on 09 March 2023, together with reference checking, citation searching, and contacting study authors to identify additional studies. We included all randomised controlled trials (RCTs) that compared fibrin sealant (fibrin glue or fibrin sealant patch) versus control (no fibrin sealant or placebo) in people undergoing pancreatic surgery. We used standard methodological procedures expected by Cochrane. We included 14 RCTs, randomising 1989 participants, comparing fibrin sealant use versus no fibrin sealant use for different locations: stump closure reinforcement (eight trials), pancreatic anastomosis reinforcement (five trials), or main pancreatic duct occlusion (two trials). Six RCTs were carried out in single centres; two in dual centres; and six in multiple centres. One RCT was conducted in Australia; one in Austria; two in France; three in Italy; one in Japan; two in the Netherlands; two in South Korea; and two in the USA. The mean age of the participants ranged from 50.0 years to 66.5 years. All RCTs were at high risk of bias. Application of fibrin sealants to pancreatic stump closure reinforcement after distal pancreatectomy We included eight RCTs involving 1119 participants: 559 were randomised to the fibrin sealant group and 560 to the control group after distal pancreatectomy. Fibrin sealant use may result in little to no difference in the rate of POPF (risk ratio (RR) 0.94, 95% confidence interval (CI) 0.73 to 1.21; 5 studies, 1002 participants; low-certainty evidence) and overall postoperative morbidity (RR 1.20, 95% CI 0.98 to 1.48; 4 studies, 893 participants; low-certainty evidence). After fibrin sealant use, approximately 199 people (155 to 256 people) out of 1000 developed POPF compared with 212 people out of 1000 when no fibrin sealant was used. The evidence is very uncertain about the effect of fibrin sealant use on postoperative mortality (Peto odds ratio (OR) 0.39, 95% CI 0.12 to 1.29; 7 studies, 1051 participants; very low-certainty evidence) and total length of hospital stay (mean difference (MD) 0.99 days, 95% CI -1.83 to 3.82; 2 studies, 371 participants; very low-certainty evidence). Fibrin sealant use may reduce the reoperation rate slightly (RR 0.40, 95% CI 0.18 to 0.90; 3 studies, 623 participants; low-certainty evidence). Serious adverse events were reported in five studies (732 participants), and there were no serious adverse events related to fibrin sealant use (low-certainty evidence). The studies did not report quality of life or cost-effectiveness. Application of fibrin sealants to pancreatic anastomosis reinforcement after pancreaticoduodenectomy We included five RCTs involving 519 participants: 248 were randomised to the fibrin sealant group and 271 to the control group after pancreaticoduodenectomy. The evidence is very uncertain about the effect of fibrin sealant use on the rate of POPF (RR 1.34, 95% CI 0.72 to 2.48; 3 studies, 323 participants; very low-certainty evidence), postoperative mortality (Peto OR 0.24, 95% CI 0.05 to 1.06; 5 studies, 517 participants; very low-certainty evidence), reoperation rate (RR 0.74, 95% CI 0.33 to 1.66; 3 studies, 323 participants; very low-certainty evidence), and total hospital cost (MD -1489.00 US dollars, 95% CI -3256.08 to 278.08; 1 study, 124 participants; very low-certainty evidence). After fibrin sealant use, approximately 130 people (70 to 240 people) out of 1000 developed POPF compared with 97 people out of 1000 when no fibrin sealant was used. Fibrin sealant use may result in little to no difference both in overall postoperative morbidity (RR 1.02, 95% CI 0.87 to 1.19; 4 studies, 447 participants; low-certainty evidence) and in total length of hospital stay (MD -0.33 days, 95% CI -2.30 to 1.63; 4 studies, 447 participants; low-certainty evidence). Serious adverse events were reported in two studies (194 participants), and there were no serious adverse events related to fibrin sealant use (very low-certainty evidence). The studies did not report quality of life. Application of fibrin sealants to pancreatic duct occlusion after pancreaticoduodenectomy We included two RCTs involving 351 participants: 188 were randomised to the fibrin sealant group and 163 to the control group after pancreaticoduodenectomy. The evidence is very uncertain about the effect of fibrin sealant use on postoperative mortality (Peto OR 1.41, 95% CI 0.63 to 3.13; 2 studies, 351 participants; very low-certainty evidence), overall postoperative morbidity (RR 1.16, 95% CI 0.67 to 2.02; 2 studies, 351 participants; very low-certainty evidence), and reoperation rate (RR 0.85, 95% CI 0.52 to 1.41; 2 studies, 351 participants; very low-certainty evidence). Fibrin sealant use may result in little to no difference in the total length of hospital stay (median 16 to 17 days versus 17 days; 2 studies, 351 participants; low-certainty evidence). Serious adverse events were reported in one study (169 participants; low-certainty evidence): more participants developed diabetes mellitus when fibrin sealants were applied to pancreatic duct occlusion, both at three months' follow-up (33.7% fibrin sealant group versus 10.8% control group; 29 participants versus 9 participants) and 12 months' follow-up (33.7% fibrin sealant group versus 14.5% control group; 29 participants versus 12 participants). The studies did not report POPF, quality of life, or cost-effectiveness. Based on the current available evidence, fibrin sealant use may result in little to no difference in the rate of POPF in people undergoing distal pancreatectomy. The evidence is very uncertain about the effect of fibrin sealant use on the rate of POPF in people undergoing pancreaticoduodenectomy. The effect of fibrin sealant use on postoperative mortality is uncertain in people undergoing either distal pancreatectomy or pancreaticoduodenectomy.

Sections du résumé

BACKGROUND
Postoperative pancreatic fistula (POPF) is one of the most frequent and potentially life-threatening complications following pancreatic surgery. Fibrin sealants have been used in some centres to reduce POPF rate. However, the use of fibrin sealant during pancreatic surgery is controversial. This is an update of a Cochrane Review last published in 2020.
OBJECTIVES
To evaluate the benefits and harms of fibrin sealant use for the prevention of POPF (grade B or C) in people undergoing pancreatic surgery compared to no fibrin sealant use.
SEARCH METHODS
We searched CENTRAL, MEDLINE, Embase, two other databases, and five trials registers on 09 March 2023, together with reference checking, citation searching, and contacting study authors to identify additional studies.
SELECTION CRITERIA
We included all randomised controlled trials (RCTs) that compared fibrin sealant (fibrin glue or fibrin sealant patch) versus control (no fibrin sealant or placebo) in people undergoing pancreatic surgery.
DATA COLLECTION AND ANALYSIS
We used standard methodological procedures expected by Cochrane.
MAIN RESULTS
We included 14 RCTs, randomising 1989 participants, comparing fibrin sealant use versus no fibrin sealant use for different locations: stump closure reinforcement (eight trials), pancreatic anastomosis reinforcement (five trials), or main pancreatic duct occlusion (two trials). Six RCTs were carried out in single centres; two in dual centres; and six in multiple centres. One RCT was conducted in Australia; one in Austria; two in France; three in Italy; one in Japan; two in the Netherlands; two in South Korea; and two in the USA. The mean age of the participants ranged from 50.0 years to 66.5 years. All RCTs were at high risk of bias. Application of fibrin sealants to pancreatic stump closure reinforcement after distal pancreatectomy We included eight RCTs involving 1119 participants: 559 were randomised to the fibrin sealant group and 560 to the control group after distal pancreatectomy. Fibrin sealant use may result in little to no difference in the rate of POPF (risk ratio (RR) 0.94, 95% confidence interval (CI) 0.73 to 1.21; 5 studies, 1002 participants; low-certainty evidence) and overall postoperative morbidity (RR 1.20, 95% CI 0.98 to 1.48; 4 studies, 893 participants; low-certainty evidence). After fibrin sealant use, approximately 199 people (155 to 256 people) out of 1000 developed POPF compared with 212 people out of 1000 when no fibrin sealant was used. The evidence is very uncertain about the effect of fibrin sealant use on postoperative mortality (Peto odds ratio (OR) 0.39, 95% CI 0.12 to 1.29; 7 studies, 1051 participants; very low-certainty evidence) and total length of hospital stay (mean difference (MD) 0.99 days, 95% CI -1.83 to 3.82; 2 studies, 371 participants; very low-certainty evidence). Fibrin sealant use may reduce the reoperation rate slightly (RR 0.40, 95% CI 0.18 to 0.90; 3 studies, 623 participants; low-certainty evidence). Serious adverse events were reported in five studies (732 participants), and there were no serious adverse events related to fibrin sealant use (low-certainty evidence). The studies did not report quality of life or cost-effectiveness. Application of fibrin sealants to pancreatic anastomosis reinforcement after pancreaticoduodenectomy We included five RCTs involving 519 participants: 248 were randomised to the fibrin sealant group and 271 to the control group after pancreaticoduodenectomy. The evidence is very uncertain about the effect of fibrin sealant use on the rate of POPF (RR 1.34, 95% CI 0.72 to 2.48; 3 studies, 323 participants; very low-certainty evidence), postoperative mortality (Peto OR 0.24, 95% CI 0.05 to 1.06; 5 studies, 517 participants; very low-certainty evidence), reoperation rate (RR 0.74, 95% CI 0.33 to 1.66; 3 studies, 323 participants; very low-certainty evidence), and total hospital cost (MD -1489.00 US dollars, 95% CI -3256.08 to 278.08; 1 study, 124 participants; very low-certainty evidence). After fibrin sealant use, approximately 130 people (70 to 240 people) out of 1000 developed POPF compared with 97 people out of 1000 when no fibrin sealant was used. Fibrin sealant use may result in little to no difference both in overall postoperative morbidity (RR 1.02, 95% CI 0.87 to 1.19; 4 studies, 447 participants; low-certainty evidence) and in total length of hospital stay (MD -0.33 days, 95% CI -2.30 to 1.63; 4 studies, 447 participants; low-certainty evidence). Serious adverse events were reported in two studies (194 participants), and there were no serious adverse events related to fibrin sealant use (very low-certainty evidence). The studies did not report quality of life. Application of fibrin sealants to pancreatic duct occlusion after pancreaticoduodenectomy We included two RCTs involving 351 participants: 188 were randomised to the fibrin sealant group and 163 to the control group after pancreaticoduodenectomy. The evidence is very uncertain about the effect of fibrin sealant use on postoperative mortality (Peto OR 1.41, 95% CI 0.63 to 3.13; 2 studies, 351 participants; very low-certainty evidence), overall postoperative morbidity (RR 1.16, 95% CI 0.67 to 2.02; 2 studies, 351 participants; very low-certainty evidence), and reoperation rate (RR 0.85, 95% CI 0.52 to 1.41; 2 studies, 351 participants; very low-certainty evidence). Fibrin sealant use may result in little to no difference in the total length of hospital stay (median 16 to 17 days versus 17 days; 2 studies, 351 participants; low-certainty evidence). Serious adverse events were reported in one study (169 participants; low-certainty evidence): more participants developed diabetes mellitus when fibrin sealants were applied to pancreatic duct occlusion, both at three months' follow-up (33.7% fibrin sealant group versus 10.8% control group; 29 participants versus 9 participants) and 12 months' follow-up (33.7% fibrin sealant group versus 14.5% control group; 29 participants versus 12 participants). The studies did not report POPF, quality of life, or cost-effectiveness.
AUTHORS' CONCLUSIONS
Based on the current available evidence, fibrin sealant use may result in little to no difference in the rate of POPF in people undergoing distal pancreatectomy. The evidence is very uncertain about the effect of fibrin sealant use on the rate of POPF in people undergoing pancreaticoduodenectomy. The effect of fibrin sealant use on postoperative mortality is uncertain in people undergoing either distal pancreatectomy or pancreaticoduodenectomy.

Identifiants

pubmed: 37335216
doi: 10.1002/14651858.CD009621.pub5
pmc: PMC10291948
doi:

Substances chimiques

Fibrin Tissue Adhesive 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD009621

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Références

J Gastrointest Surg. 2011 Sep;15(9):1625-9
pubmed: 21671113
HPB (Oxford). 2017 Jun;19(6):515-524
pubmed: 28202218
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Br J Surg. 2022 Oct 14;109(11):1131-1139
pubmed: 35983583
Cochrane Database Syst Rev. 2021 Jan 20;1:CD011490
pubmed: 33471373
HPB (Oxford). 2020 Aug;22(8):1092-1101
pubmed: 32471694
J Clin Med. 2020 Sep 24;9(10):
pubmed: 32987876
J Hepatobiliary Pancreat Sci. 2019 Mar;26(3):96-103
pubmed: 30589508
World J Surg. 2019 Dec;43(12):3128-3137
pubmed: 31502003
Cochrane Database Syst Rev. 2018 Jun 23;6:CD009621
pubmed: 29934987
Ital J Gastroenterol. 1994 Jul-Aug;26(6):283-6
pubmed: 7949264
Clin Gastroenterol Hepatol. 2021 May;19(5):876-884
pubmed: 32147593
Ann Surg. 2016 Aug;264(2):344-52
pubmed: 26727086
J Gastrointest Surg. 2009 Jul;13(7):1396-8; author reply 1399-400
pubmed: 19381733
Ann Surg. 2003 Jan;237(1):57-65
pubmed: 12496531
HPB (Oxford). 2022 Jan;24(1):72-78
pubmed: 34176743
Pancreatology. 2014 Nov-Dec;14(6):490-6
pubmed: 25224249
World J Surg. 2016 Nov;40(11):2771-2781
pubmed: 27343014
J Am Coll Surg. 2010 Jul;211(1):114-25
pubmed: 20610257
Best Pract Res Clin Gastroenterol. 2008;22(1):45-63
pubmed: 18206812
Acta Chir Belg. 2021 Feb;121(1):16-22
pubmed: 31433745
Surgery. 2017 Mar;161(3):584-591
pubmed: 28040257
J Gastrointest Surg. 2004 Nov;8(7):766-72; discussion 772-4
pubmed: 15531229
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Am J Surg. 1960 Jun;99:898-903
pubmed: 13808137
Ann Med Surg (Lond). 2021 Mar 26;64:102244
pubmed: 33898024
Cochrane Database Syst Rev. 2017 Sep 12;9:CD012257
pubmed: 28898386
Cochrane Database Syst Rev. 2016 Feb 15;2:CD009621
pubmed: 26876721
Surg Innov. 2015 Dec;22(6):601-5
pubmed: 25857807
World J Surg. 2010 Apr;34(4):632-4
pubmed: 19820991
Br J Surg. 1987 May;74(5):392-4
pubmed: 3594133
J Hepatobiliary Pancreat Surg. 2005;12(4):283-5
pubmed: 16133693
Expert Opin Biol Ther. 2009 Jul;9(7):897-907
pubmed: 19527109
Presse Med. 2019 Mar;48(3 Pt 2):e113-e123
pubmed: 30878335
Pancreas. 2008 Apr;36(3):261-6
pubmed: 18362839
HPB (Oxford). 2015 Nov;17(11):1033-9
pubmed: 26292846
Ann Surg. 2019 Nov;270(5):791-798
pubmed: 31567180
Am J Otolaryngol. 2001 Jul-Aug;22(4):230-5
pubmed: 11464318
Langenbecks Arch Surg. 2016 Mar;401(2):151-9
pubmed: 26897031
BJS Open. 2021 May 7;5(3):
pubmed: 34137446
Surgery. 2005 Jul;138(1):8-13
pubmed: 16003309
Arch Surg. 1995 Sep;130(9):952-5
pubmed: 7661678
Cochrane Database Syst Rev. 2016 May 06;(5):CD008914
pubmed: 27153248
ANZ J Surg. 2021 Nov;91(11):2459-2465
pubmed: 34514684
J Gastroenterol Hepatol. 2014;29(7):1342
pubmed: 25040619
Expert Rev Med Devices. 2019 Mar;16(3):253-256
pubmed: 30757929
Cochrane Database Syst Rev. 2003;(2):CD004171
pubmed: 12804501
Cochrane Database Syst Rev. 2013 Apr 30;(4):CD008370
pubmed: 23633353
Lancet. 2020 Jun 27;395(10242):2008-2020
pubmed: 32593337
Dig Liver Dis. 2017 May;49(5):535-539
pubmed: 28089214
Cochrane Database Syst Rev. 2020 Mar 11;3:CD009621
pubmed: 32157697
Am J Surg. 2015 Oct;210(4):739-48
pubmed: 26160763
Cochrane Database Syst Rev. 2021 Dec 18;12:CD010583
pubmed: 34921395
Facial Plast Surg Clin North Am. 2002 May;10(2):147-54
pubmed: 15062317
World J Surg. 1998 May;22(5):494-8
pubmed: 9564295
HPB (Oxford). 2013 Aug;15(8):561-6
pubmed: 23458447
HPB (Oxford). 2014 Jan;16(1):3-11
pubmed: 23461684
Ann Surg. 2019 May;269(5):937-943
pubmed: 29240007
J Gastrointest Surg. 2009 Jul;13(7):1184-6
pubmed: 19399562
Ann Surg. 2022 Jul 7;:
pubmed: 35797608
J Gastrointest Surg. 2013 Jan;17(1):102-9
pubmed: 22798186
Ann Surg. 2007 Feb;245(2):222-31
pubmed: 17245175
Br J Surg. 2018 Jun;105(7):811-819
pubmed: 29664999
Pancreatology. 2019 Sep;19(6):813-818
pubmed: 31350077
Nat Rev Gastroenterol Hepatol. 2021 Jul;18(7):493-502
pubmed: 34002083
Acta Oncol. 2016 Sep - Oct;55(9-10):1158-1160
pubmed: 27551890
JAMA. 2019 Dec 24;322(24):2422-2434
pubmed: 31860051
J Gastrointest Surg. 2019 Sep;23(9):1817-1824
pubmed: 30478529
Ann Surg Open. 2021 Feb 10;2(1):e033
pubmed: 37638240
Lancet. 2020 Aug 15;396(10249):499-512
pubmed: 32798493
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
J Hepatobiliary Pancreat Sci. 2016 Feb;23(2):110-7
pubmed: 26681272
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):934-947
pubmed: 31648972
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Gastroenterol Clin Biol. 2006 Jun-Jul;30(6-7):838-44
pubmed: 16885867
Ann Surg. 2012 Nov;256(5):853-9; discussion 859-60
pubmed: 23095631
J Am Coll Surg. 2013 Jan;216(1):1-14
pubmed: 23122535
J Gastrointest Surg. 2010 May;14(5):884-90
pubmed: 20177808
Minerva Chir. 2015 Jun;70(3):175-80
pubmed: 25960031
J Gastroenterol Hepatol. 2004 Sep;19(9):998-1004
pubmed: 15304116
Dig Surg. 2009;26(1):7-14
pubmed: 19145082
Ann Med Surg (Lond). 2021 Jun 29;67:102531
pubmed: 34276983
Ann Surg. 2002 Oct;236(4):422-8; discussion 428
pubmed: 12368670
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120

Auteurs

Mingliang Lai (M)

Department of Clinical Laboratory, Chongqing University Jiangjin Hospital, School of Medicine, Chongqing University, Chongqing, China.

Shiyi Zhou (S)

Department of Pharmacy, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.

Sirong He (S)

Department of Hepatobiliary Surgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.

Yao Cheng (Y)

Department of Hepatobiliary Surgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.

Nansheng Cheng (N)

Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, China.

Yilei Deng (Y)

Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Xiong Ding (X)

Department of Hepatobiliary Surgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH